Theravance Biopharma Inc (TBPH) was Downgraded by BofA/Merrill to ” Underperform”. Earlier the firm had a rating of “Neutral ” on the company shares. BofA/Merrill advised their investors in a research report released on Aug 3, 2016.
Many Wall Street Analysts have commented on Theravance Biopharma Inc. Guggenheim Initiated Theravance Biopharma Inc on Jun 20, 2016 to “Buy”, Price Target of the shares are set at $30.Company shares were Reiterated by Leerink Partners on Jun 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 29 from a previous price target of $26 .Leerink Partners Initiated Theravance Biopharma Inc on May 12, 2016 to “Outperform”, Price Target of the shares are set at $26.
Theravance Biopharma Inc opened for trading at $26.46 and hit $27.5899 on the upside on Tusday, eventually ending the session at $27.26, with a gain of 3.26% or 0.86 points. The heightened volatility saw the trading volume jump to 3,05,891 shares. Company has a market cap of $1,294 M.
In a different news, on Aug 18, 2015, Junning Lee (Sr. VP, Technical Operations) purchased 9,000 shares at $12.90 per share price. According to the SEC, on Aug 18, 2015, Burton G Malkiel (director) purchased 10,000 shares at $12.92 per share price. On Aug 17, 2015, Renee D Gala (CFO) purchased 10,000 shares at $12.18 per share price, according to the Form-4 filing with the securities and exchange commission.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.